Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	45.16B +152.5%
Revenue (ttm)	4.32B +248.9%
Net Income	2.97B +315.2%
EPS	4.78 +312.5%
Shares Out	618.09M
PE Ratio	15.27
Forward PE	70.26
Dividend	0.48 (0.66%)
Ex-Dividend Date	Nov 7, 2025

Volume	6,205,118
Average Volume	10,311,921
Open	72.88
Previous Close	73.19
Day's Range	72.00 - 73.98
52-Week Range	26.80 - 96.60
Beta	0.44
RSI	41.51
Earnings Date	Aug 21, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,012
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.90 billion, an increase of 311.49%.